CompletedPhase 2

Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

Canada1 participantsStarted 2021-03-29

Plain-language summary

NRG1 gene fusions are extremely rare across solid tumours (estimate 0.3-0.5%). However, it is felt to be an actionable and potentially major growth pathway for those tumours that harbour this gene rearrangement. Tumours that harbour NRG1 fusions are driven by HER3 overactivation. Seribantumab is a mono-clonal antibody against HER3, it binds HER3 and inhibits NRG1-dependent activation and HER2 dimerization.

Who can participate

Age range18 Years – 60 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Serious, life-threatening condition * Not eligible for, or exhausted all other treatment options or causing significant toxicity * No other way to access treatment Exclusion Criteria: \-

What they're measuring

Overall survival

Timeframe: 1 year

Trial details

NCT IDNCT04790695

SponsorOttawa Hospital Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-22

View on ClinicalTrials.gov More Metastatic Pancreatic Cancer trials